DrugPatentWatch Database Preview
Ibritumomab tiuxetan - Biologic Drug Details
Email this page to a colleague
» See Plans and PricingSummary for ibritumomab tiuxetan
| Tradenames: | 1 |
| Patents: | 154 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for ibritumomab tiuxetan |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ibritumomab tiuxetan |
Recent Clinical Trials for ibritumomab tiuxetan
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 3 |
| University of California, Davis | Phase 2 |
| Spectrum Pharmaceuticals, Inc | Phase 3 |
Recent Litigation for ibritumomab tiuxetan
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| GENENTECH, INC. v. CELLTRION, INC. | 2018-01-12 |
| GENENTECH, INC. v. SANDOZ, INC. | 2017-12-21 |
| Biogen Idec, Inc. v. Glaxosmithkline LLC | 2010-03-24 |
Company Disclosures: US Patents for ibritumomab tiuxetan
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Idec Pharmaceuticals Corporation (San Diego, CA) | 2015-04-07 | RX | Orphan | company |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | IDEC Pharmaceuticals Corporation (San Diego, CA) | 2015-07-07 | RX | Orphan | company |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | 2015-12-01 | RX | Orphan | company | |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | IDEC Pharmaceuticals Corporation (San Diego, CA) | 2039-03-29 | RX | Orphan | company |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | IDEC Pharmaceutical Corporation (San Diego, CA) | 2019-06-04 | RX | Orphan | company |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | IDEC Pharmaceuticals Corporation (San Diego, CA) | 2021-01-27 | RX | Orphan | company |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Biogen IDEC Inc. (Cambridge, MA) | 2019-03-01 | RX | Orphan | company |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for ibritumomab tiuxetan
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Schering Corpoartion (Kenilworth, NJ) | 2022-09-04 | RX | Orphan | search |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Schering Corporation (Kenilworth, NJ) | 2022-09-04 | RX | Orphan | search |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Schering Corporation (Kenilworth, NJ) | 2022-09-04 | RX | Orphan | search |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Human Genome Sciences, Inc. (Rockville, MD) The Regents of the University of Michigan (Ann Arbor, MI) | 2017-01-28 | RX | Orphan | search |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Momenta Pharmaceuticals, Inc. (Cambridge, MA) | 2023-10-01 | RX | Orphan | search |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Idera Pharmaceuticals, Inc. (Cambridge, MA) | 2023-05-16 | RX | Orphan | search |
| Spectrum Pharms | ZEVALIN | ibritumomab tiuxetan | INJECTABLE; INJECTION | 125019 | 001 | 2002-02-19 | Start Trial | Bayer Schering Pharma Aktiengesellschaft (Berlin, DE) | 2024-09-06 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for ibritumomab tiuxetan
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hong Kong | 1109633 | Start Trial |
| China | 1649902 | Start Trial |
| Hong Kong | 1138885 | Start Trial |
| Poland | 1976532 | Start Trial |
| Mexico | 340090 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2014068443 | Start Trial |
| China | 107801378 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ibritumomab tiuxetan
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0669836/01 | Switzerland | Start Trial | FORMER OWNER: BIOGEN INC., US |
| 2004000036 | Germany | Start Trial | FORMER OWNER: BIOGEN IDEC INC.(N.D.GES.D.STAATES DELAWARE), SAN DIEGO, CALIF., US |
| 2016000070123 | Italy | Start Trial | PRODUCT NAME: RITUXIMAB IN ASSOCIAZIONE CON IALURONIDASI RICOMBINANTE UMANA - SOLUZIONE PER INIEZIONE SOTTOCUTANEA(MABTHERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/98/067/001-003, 20140326 |
| C/GB04/025 | United Kingdom | Start Trial | PRODUCT NAME: IBRITUMOMAB COMPRISING A CHELATING AGENT FOR YTTRIUM (90); REGISTERED: UK EU/1/03/264/001 20040116 |
| 2016 00031 | Denmark | Start Trial | PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326 |
| 2004901230024 | Italy | Start Trial | PRODUCT NAME: IBRITUMOMAB(ZEVALIN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/03/264/001, 20040116 |
| 2000149/01 | Switzerland | Start Trial | PRODUCT NAME: RITUXIMABUM; REGISTRATION NO/DATE: IKS 54378 19971127 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
